Global Market for Circulating Tumor Cells Prognostic Technologies to be Driven by Technological Advancements

Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease. These rare cells are found both in the bone marrow and in peripheral blood of the body. However, the CTCs found in the blood usually have a short survival time as compared to CTCs found in the bone marrow, which makes the analysis of blood sample for CTCs more specific, thus known as “liquid biopsy”. Therefore, detection of CTCs during the progression of the tumor provides a prognostic value of the tumor progression as well as evaluates the efficacy of therapeutic intervention and provides necessary information for developing personalized medicines.

Get Report Sample @

By technology, the two major segments of the global market for CTCs prognostic technologies include tumor cell detection and tumor cell enrichment. The tumor cell detection segment is further sub-segmented into optical methods and molecular methods. Among these segments, the optical methods segment is projected to exhibit 27.30% CAGR from 2014 to 2020. On the other hand, the tumor cell enrichment segment is divided into immunological and immunomagnetic methods, filtration, and centrifugation. In these sub-segments, immunomagnetic methods accounted for the largest share in the overall tumor cell enrichment segment.

By application, the global market for CTCs prognostic technologies has been classified into colorectal cancer, breast cancer, prostate cancer, and others (such as ovarian cancer, lung cancer, and pancreatic cancer). Among these, the prostate cancer segment is estimated to exhibit 25.20% CAGR; whereas, the breast cancer segment is expected to register 27.10% CAGR between 2014 and 2020.

Geographically, the global market for CTCs prognostic technologies has been segmented into Europe, North America, Asia Pacific, and Rest of the World. Among all these regions, North America dominated the overall CTCs prognostic technologies market. The high growth of this region can be attributed to the rising prevalence rate of cancer and increasing adoption of advanced prognostic technologies. On the other hand, Asia Pacific is also expected to register steady growth in the forecast period owing to the estimated rise in different types of cancers along with several research and development initiatives taken by the governments and major players.

View Report @

Leave a Reply